Last Updated on October 12, 2024 by The Health Master
DCGI approval
DCGI approval
DCGI approval: Urinary tract infections (UTIs) are a common ailment, but complicated UTIs (cUTIs) pose a significant challenge.
These infections often involve multi-drug resistant bacteria, making treatment difficult.
The recent DCGI approval granted by India’s Drug Controller General of India (DCGI) for Orchid Pharma’s new antibiotic drug combination offers a promising solution.
Effective Treatment for cUTIs
Orchid Pharma has received DCGI approval to manufacture and market a new drug formulation specifically designed to address cUTIs.
This injectable combination consists of Cefepime, a powerful broad-spectrum antibiotic, and Enmetazobactam, a novel beta-lactamase inhibitor developed by Orchid Pharma itself.
Enmetazobactam’s role is crucial – it protects Cefepime from being rendered ineffective by certain bacteria, ensuring the antibiotic’s potency.
Threat of Anti-Microbial Resistance (AMR)
The emergence of antibiotic-resistant bacteria is a global health crisis.
The World Health Organization (WHO) has declared AMR a “silent pandemic,” and the United Nations estimates it contributed to nearly 5 million deaths in 2019 alone.
This highlights the urgent need for new and effective antibiotics.
Beyond Treatment
The impact of AMR goes beyond mortality rates.
The World Bank estimates that by 2050, AMR could lead to an additional $1 trillion in healthcare costs and annual GDP losses ranging from $1 trillion to $3.4 trillion.
Effectively treating infections with antibiotics like Orchid Pharma’s new drug can significantly contribute to curbing these economic burdens.
A Hopeful Future for cUTI Patients
Orchid Pharma’s achievement is a significant step forward in the fight against cUTIs and AMR.
The company’s Managing Director, Manish Dhanuka, expressed his pride in developing this solution, particularly for patients in India.
The successful launch and distribution of this drug combination have the potential to revolutionize the treatment landscape for severe infections, offering a much-needed weapon in the ongoing battle against antibiotic resistance.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
DCGI: Withdraw Cancer drug ‘Olaparib’ for these treatments
DCGI to SLAs: Cancel this Antibiotic Drug Combination
DCGI to Collaborate with Stakeholders: Empowering Ease of Doing Business
DCGI issues Guidelines on Sampling of Drugs
DCGI to Blood Centres: Comply with revised guidelines for recovery of processing charges
Gujarat FDCA Cracks Down on Medical Stores: Licenses cancelled
Gujarat FDCA Cracks Down on Pharmaceutical Manufacturing Violations
CDSCO Panel Approves Benralizumab Solution For Injection In Auto-Injector
BIS Standards for Medical Device Testing in India
NABL Clarifies Test Method for Blood-Resistant PPE
Govt issues instructions on marketing codes of pharma companies
Nutraceuticals in Drug Units: Panel to examine the issue
CDSCO underscores stringent compliance to Revised Schedule M
USFDA issues OAI status to Eugia Pharma of Aurobindo
Can Your Air Handling Meet the new Schedule M? Find Out Here
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
